What is the average price target for FIBROGEN INC (FGEN) stock?
8 analysts have analysed FGEN and the average price target is 43.86 USD. This implies a price increase of 351.7% is expected in the next year compared to the current price of 9.71.
FIBROGEN INC (FGEN) Forecast, Price Target & Analyst Ratings
NASDAQ:FGEN • US31572Q8814
Current stock price
9.71 USD
+0.69 (+7.65%)
At close:
9.75 USD
+0.04 (+0.41%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FIBROGEN INC (FGEN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 16, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$3.96
- Revenue Estimate
- 1.703M
Price Target Details & History
Consensus Price Target and Range
Mean target
$43.86
Upside
+ 351.70%
From current price of $9.71 to mean target of $43.86, Based on 8 analyst forecasts
Low
$43.43
Median
$43.86
High
$45.15
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for FGEN. The average price target is 43.86 USD. This implies a price increase of 351.7% is expected in the next year compared to the current price of 9.71.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
FGEN was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about FGEN.
In the previous month the buy percentage consensus was at a similar level.
FGEN was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-08 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2023-06-27 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-06-27 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-06-26 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-06-26 | Stifel | Downgrade | Buy -> Hold |
| 2023-06-26 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-06-26 | B of A Securities | Downgrade | Buy -> Neutral |
| 2023-06-02 | Stifel | Upgrade | Hold -> Buy |
| 2023-02-28 | Cowen & Co. | Maintains | Market Perform |
| 2023-02-23 | Goldman Sachs | Maintains | Sell |
| 2023-02-21 | Goldman Sachs | Maintains | Sell |
| 2023-01-31 | William Blair | Upgrade | Market Perform -> Outperform |
| 2023-01-26 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2023-01-05 | B of A Securities | Upgrade | Neutral -> Buy |
| 2022-11-08 | Goldman Sachs | Maintains | Sell |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-03-01 | Goldman Sachs | Maintains | Sell |
| 2021-09-22 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2021-08-20 | Raymond James | Upgrade | Underperform -> Market Perform |
| 2021-08-10 | SVB Leerink | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 16, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$3.96
- Revenue Estimate
- 1.703M
- Revenue Q2Q
- -96.62%
- EPS Q2Q
- -188.06%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.29%
EPS (1 Month)
10.69%
EPS (3 Months)
6.83%
Next Earnings Summary
FGEN is expected to report earnings on 3/16/2026. The consensus EPS estimate for the next earnings is -3.96 USD and the consensus revenue estimate is 1.70M USD.
The next earnings revenue estimate has been revised upward by 0.29% in the past 3 months.
Full Analyst Estimates 2025 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 140.7M -40.20% | 46.803M -66.74% | 29.621M -36.71% | 6.885M -76.76% | 6.242M -9.34% | 6.242M | 6.324M 1.31% | 286.62M 4,432.26% | 294.78M 2.85% | |
| EBITDA YoY % growth | -290.4M -6.11% | -300.185M -3.37% | -128.27M 57.27% | -46.308M 63.90% | -47.226M -1.98% | -51.918M -9.94% | -57.528M -10.81% | N/A | N/A | |
| EBIT YoY % growth | -301M -4.33% | -310.115M -3.03% | -130.962M 57.77% | -46.614M 64.41% | -48.603M -4.27% | -58.599M -20.57% | -57.528M 1.83% | 31.62M 154.96% | 41.82M 32.26% | |
| Operating Margin | -213.93% | -662.60% | -442.13% | -677.04% | -778.64% | -938.79% | -909.68% | 11.03% | 14.19% | |
| EPS YoY % growth | -78.50 | -70.00 10.83% | -12.00 82.86% | -4.70 60.86% | -12.19 -159.50% | -10.87 10.84% | -7.05 35.15% | 0.26 103.62% | 0.31 20.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.96 -188.06% | -4.38 -450.06% | -4.34 -130.59% | -4.53 -39.35% | -4.49 -13.26% | -4.17 4.66% | -4.60 -6.12% | -5.02 -10.81% | -4.97 -10.68% | -4.92 -17.85% | -4.87 -5.76% | -4.81 4.07% | -4.77 3.90% |
| Revenue Q2Q % growth | 1.703M -96.62% | 1.54M -43.78% | 1.54M 14.24% | 1.54M 43.12% | 1.54M -9.57% | 1.54M | 1.54M | 1.54M | 1.54M | 1.54M | 1.54M | 1.54M | 1.54M |
| EBITDA Q2Q % growth | -13.26M 84.94% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.28M 84.27% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
3.05%
EPS Next 5 Year
15.11%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-67.47%
Revenue Next 5 Year
9.58%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
7.86%
EBIT Next 5 Year
4.10%
FIBROGEN INC / FGEN Forecast FAQ
When does FIBROGEN INC (FGEN) report earnings?
FIBROGEN INC (FGEN) will report earnings on 2026-03-16, after the market close.
What are the consensus estimates for FGEN stock next earnings?
The consensus EPS estimate for the next earnings of FIBROGEN INC (FGEN) is -3.96 USD and the consensus revenue estimate is 1.70M USD.
What is the consensus rating for FGEN stock?
The consensus rating for FIBROGEN INC (FGEN) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.